This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Kürkciyan, I. Articles by Laggner, A. N. Search for Related Content PubMed PubMed Citation Articles by Kürkciyan, I. Articles by Laggner, A. N. Social Bookmarking                         What's this?

A New Preparation of Nifedipine for Sublingual Application in Hypertensive Urgencies

Emergency Department, University of Vienna

Fritz Sterz

Emergency Department, University of Vienna

Michael Roden

Emergency Department, University of Vienna

Gottfried Heinz

Clinic of Internal Medicine , Department of Cardiology, University of Vienna, Vienna, Austria

Michael M. Hirschl

Emergency Department, University of Vienna

Marcus Müllner

Emergency Department, University of Vienna

Anton Norbert Laggner

Emergency Department, University of Vienna

A new preparation of nifedipine for sublingual application in hypertensive urgencies was investigated in a prospective study. Patients admitted to the Emergency Department with a persistent elevation of systolic blood pressure (SBP) greater than 190 mm Hg and/or a diastolic blood pressure (DBP) greater than 100 mm Hg received nifedipine 10 mg sublin gual with a sprayer. A second dose was administrated fifteen minutes later if an adequate response defined as a stable reduction of SBP below 180 mm Hg and DBP below 100 mm Hg had not occurred. Of 30 patients, 21 (70%) responded to the first nifedipine appli cation, 7 responded to the second dose, and 2 nonresponders had to be treated with urapidil. Overall mean SBP was 206 ± 19 mm Hg and mean DBP was 113 ± 15 mm Hg before treatment, and a significant antihypertensive effect was noted within fifteen minutes after nifedipine spray (p < 0.05). The maximum antihypertensive effect was for SBP in sixty minutes (146 ±19 mm Hg) and for DBP after one hundred twenty minutes (78 ± 18 mm Hg). The average reduction in SBP was 29% and in DBP 31%. In first-dose responders (n = 21) a significant antihypertensive effect was noted within fifteen minutes. SBP declined from 205 ±21 to a minimum of 142 ±15 mm Hg (22.3%) after sixty minutes and DBP from 113 ± 13 to a minimum of 77 ±11 mm Hg (22.2%) after one hundred twenty minutes. In second-dose responders (n = 7) a significant antihypertensive effect was noted within thirty minutes. SBP declined from 214 ±20 to a minimum of 151 ± 18 mm Hg (29.5%) after sixty minutes and DBP from 123 ± 14 to a minimum of 92 ±31 mm Hg (24.9%) after one hundred twenty minutes. After treatment with sublin gual nifedipine spray the authors could not observe any clinically significant side effects. Overall the heart rate decreased significantly from 100 ±21 beats per minute to a minimum of 84 ± 15 beats per minute after one hundred twenty minutes. The authors conclude that sublingual nifedipine spray application offers a new, highly effective, safe, and convenient method of treating patients with hypertensive urgencies.

Angiology, Vol. 45, No. 7, 629-635 (1994)
DOI: 10.1177/000331979404500706


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?